Immune thrombocytopenia: Antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro

Haematologica

Volumn 100, Issue 5, 2015, Pages 623-632

  Iraqi, Muna ^a,b   Perdomo, Jose ^a,b   Yan, Feng ^a,b,c   Choi, Philip Y I ^a,b   Chong, Beng H ^a,b,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST GEORGE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPLATELET AUTOANTIBODY; AUTOANTIBODY; CASPASE; ELTROMBOPAG; ROMIPLOSTIM; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; THROMBOPOIETIN RECEPTOR;

ADULT; AGED; ARTICLE; CD34 SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MEGAKARYOCYTE; PROTEIN PURIFICATION; THROMBOCYTE RELEASE REACTION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; AGONISTS; BLOOD; CASE CONTROL STUDY; CELL DIFFERENTIATION; CELL SIZE; CYTOLOGY; DRUG EFFECTS; ENZYME ACTIVATION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOLOGY; LEUKOCYTE COUNT; METABOLISM; MIDDLE AGED; PLOIDY; THROMBOCYTE; THROMBOCYTE COUNT; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; BLOOD PLATELETS; CASE-CONTROL STUDIES; CASPASES; CELL DIFFERENTIATION; CELL SIZE; ENZYME ACTIVATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; LEUKOCYTE COUNT; MALE; MEGAKARYOCYTES; MIDDLE AGED; PLATELET COUNT; PLOIDIES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, THROMBOPOIETIN; YOUNG ADULT;

EID: 84929150946     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.115634     Document Type: Article

References (47)

1. McMillan R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin North Am. 2009;23(6):1163-1175.
2. Brighton TA, Evans S, Castaldi PA, et al. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood. 1996;88(1):194-201.
3. McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol. 2000;37(3):239-248.
4. Isaka Y, Kambayashi J, Kimura K, et al. Platelet production, clearance and distribution in patients with idiopathic thrombocytopenic purpura. Thromb Res. 1990;60(2): 121-131.
5. Siegel RS, Rae JL, Barth S, et al. Platelet survival and turnover: important factors in predicting response to splenectomy in immune thrombocytopenic purpura. Am J Hematol. 1989;30(4):206-212.
6. Abgrall JF, Berthou C, Sensebe L, et al. Decreased in vitro megakaryocyte colony formation in chronic idiopathic thrombocytopenic purpura. Br J Haematol. 1993;85(4): 803-804.
7. Alimardani G, Guichard J, Fichelson S, et al. Pathogenic effects of anti-glycoprotein Ib antibodies on megakaryocytes and platelets. Thromb Haemost. 2002;88(6):1039-1046.
8. McMillan R, Wang L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004; 103(4):1364-1369.
9. Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102(3):887-895.
10. Yang L, Wang L, Zhao CH, et al. Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia. Blood. 2010; 116(20):4307-4316.
11. Takahashi R, Sekine N, Nakatake T. Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony formation and proplatelet formation. Blood. 1999;93(6):1951-1958.
12. Perdomo J, Yan F, Ahmadi Z, et al. Quinineinduced thrombocytopenia: drug-dependent GPIb/IX antibodies inhibit megakaryocyte and proplatelet production in vitro. Blood. 2011;117(22):5975-5986.
13. Barsam SJ, Psaila B, Forestier M, et al. Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood. 2011; 117(21):5723-5732.
14. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115(2):168-186.
15. Dati F, Schumann G, Thomas L, et al. Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP reference material (CRM 470). International Federation of Clinical Chemistry. Community Bureau of Reference of the Commission of the European Communities. College of American Pathologists. Eur J Clin Chem Clin Biochem. 1996;34(6):517-520.
16. Currao M, Balduini CL, Balduini A. High doses of romiplostim induce proliferation and reduce proplatelet formation by human megakaryocytes. PLoS One. 2013;8(1): e54723.
17. Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009; 27(2):424-430.
18. Tao H, Gaudry L, Rice A, et al. Cord blood is better than bone marrow for generating megakaryocytic progenitor cells. Exp Hematol. 1999;27(2):293-301.
19. Perdomo J, Yan F, Chong BH. A megakaryocyte with no platelets: anti-platelet antibodies, apoptosis, and platelet production. Platelets. 2013;24(2):98-106.
20. White MJ, Schoenwaelder SM, Josefsson EC, et al. Caspase-9 mediates the apoptotic death of megakaryocytes and platelets, but is dispensable for their generation and function. Blood. 2012;119(18):4283-4290.
21. Han ZC, Sensebe L, Abgrall JF, et al. Platelet factor 4 inhibits human megakaryocytopoiesis in vitro. Blood. 1990;75(6):1234-1239.
22. Han ZC, Bellucci S, Wan HY, et al. New insights into the regulation of megakaryocytopoiesis by haematopoietic and fibroblastic growth factors and transforming growth factor beta 1. Br J Haematol. 1992;81(1):1-5.
23. Kuter DJ, Gminski DM, Rosenberg RD. Transforming growth factor beta inhibits megakaryocyte growth and endomitosis. Blood. 1992;79(3):619-626.
24. Dong M, Blobe GC. Role of transforming growth factor-beta in hematologic malignancies. Blood. 2006;107(12):4589-4596.
25. Kuter DJ. Biology and chemistry of thrombopoietic agents. Semin Hematol. 2010; 47(3):243-248.
26. Vainchenker W, Deschamps JF, Bastin JM, et al. Two monoclonal antiplatelet antibodies as markers of human megakaryocyte maturation: immunofluorescent staining and platelet peroxidase detection in megakaryocyte colonies and in in vivo cells from normal and leukemic patients. Blood. 1982; 59(3):514-521.
27. Hoffman R, Zaknoen S, Yang HH, et al. An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. N Engl J Med. 1985;312(18):1170-1174.
28. McMillan R, Luiken GA, Levy R, et al. Antibody against megakaryocytes in idiopathic thrombocytopenic purpura. JAMA. 1978; 239(23):2460-2462.
29. Stahl CP, Zucker-Franklin D, McDonald TP. Incomplete antigenic cross-reactivity between platelets and megakaryocytes: relevance to ITP. Blood. 1986;67(2):421-428.
30. Wang L, Li Y, Hou M. Idiopathic thrombocytopenic purpura and dysmegakaryocytopoiesis. Crit Rev Oncol Hematol. 2007; 64(2):83-89.
31. Gewirtz AM. Megakaryocytopoiesis: the state of the art. Thromb Haemost. 1995; 74(1):204-209.
32. Hartwig J, Italiano JE Jr. The birth of the platelet. J Thromb Haemost. 2003;1(7):1580-1586.
33. Italiano JE Jr, Lecine P, Shivdasani RA, et al. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell Biol. 1999;147(6):1299-1312.
34. Patel SR, Hartwig JH, Italiano JE Jr. The biogenesis of platelets from megakaryocyte proplatelets. J Clin Invest. 2005;115(12):3348-3354.
35. Stasi R. The stingy bone marrow and the wasteful peripheral blood: a tale of two ITPs. Blood. 2011;117(21):5553-5554.
36. Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood. 1995;85(7):1719-1726.
37. Faulhaber M, Wormann B, Ganser A, et al. In vitro response of myelodysplastic megakaryocytopoiesis to megakaryocyte growth and development factor (MGDF). Ann Hematol. 2002;81(12):695-700.
38. Tajika K, Nakamura H, Nakayama K, et al. Thrombopoietin can influence mature megakaryocytes to undergo further nuclear and cytoplasmic maturation. Exp Hematol. 2000;28(2):203-209.
39. Zeng Q, Zhu L, Tao L, et al. Relative efficacy of steroid therapy in immune thrombocytopenia mediated by anti-platelet GPIIbIIIa versus GPIbalpha antibodies. Am J Hematol. 2012;87(2):206-208.
40. Webster ML, Sayeh E, Crow M, et al. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood. 2006;108(3):943-946.
41. Peng J, Ma SH, Liu J, et al. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. J Thromb Haemost. 2014;12 (4):497-504.
42. Melloni E, Secchiero P, Celeghini C, et al. Functional expression of TRAIL and TRAILR2 during human megakaryocytic development. J Cell Physiol. 2005;204(3):975-982.
43. Arabanian LS, Kujawski S, Habermann I, et al. Regulation of fas/fas ligand-mediated apoptosis by nuclear factor of activated T cells in megakaryocytes. Br J Haematol. 2012;156(4):523-534.
44. Broudy VC and Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine. 2004;25(2):52-60.
45. Leon C, Evert K, Dombrowski F, et al. Romiplostim administration shows reduced megakaryocyte response-capacity and increased myelofibrosis in a mouse model of MYH9-RD. Blood. 2012;119(14):3333-3341.
46. Kuter DJ, Gernsheimer TB. Thrombopoietin and platelet production in chronic immune thrombocytopenia. Hematol Oncol Clin North Am. 2009;23(6):1193-1211.
47. Lev PR, Grodzielski M, Goette NP, et al. Impaired proplatelet formation in immune thrombocytopenia: a novel mechanism contributing to decreased platelet count. Br J Haematol. 2014; 165(6):854-864.